From a translational perspective, the potential to improve the response to cancer immunotherapy (pursued in clinical trial NCT04725474) and to ameliorate cancer- and chemotherapy-associated cachexia17,64 (pursued in studies NCT04815551 & NCT04299048) provides two compelling reasons for the further clinical exploration of GDF-15-neutralizing cancer treatments. The gene discussed is GDF15; the disease is cancer.